Quetiapine half-life
Quetiapine labeling and clinical review support a parent-drug half-life near six hours.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Quetiapine: evidence and interpretation notes
What the representative value means
Quetiapine labeling and clinical review support a parent-drug half-life near six hours. Norquetiapine, formulation, age, and CYP3A interactions add context that the parent curve cannot display.
The calculator follows Quetiapine with a 6-hour half-life. That simplification is useful for curve shape and comparison, but it is not an individualized pharmacokinetic estimate.
Quetiapine has clinical effects that depend on dose, formulation, receptors, patient factors, and repeated use. The chart only represents simplified elimination of the selected value.
What each source contributes
- DailyMed: QUETIAPINE FUMARATE (QUETIAPINE) TABLET [COUPLER LLC]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Quetiapine. This identity record confirms names and compound identity and does not supply a human half-life.
- Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
For Quetiapine, the numerical model is tied most closely to DailyMed: QUETIAPINE FUMARATE (QUETIAPINE) TABLET [COUPLER LLC]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why there is no range on the chart
This profile plots 6 hours for Quetiapine without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 6 h as a representative input for Quetiapine. In the simplified model, about 6.3% remains after 24 hours and about 3% remains after five half-lives, or roughly 30 h.
This sits in the same-day range. The chart is useful for seeing the bend of the curve across a day or two, but it should not be treated as a personal clock. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
antipsychotic context
Antipsychotic half-life estimates can involve long distribution phases, active metabolites, depot or extended-release formulations, and clinically important steady-state timing.
- Half-life is not a measure of symptom control or adverse-effect duration.
- Depot and extended-release products should not be compared directly with immediate-release values.
- Treatment changes require clinician-guided interpretation beyond a single curve.
ComparisonTimeline checkpoints and nearby profiles
Quetiapine timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 12 h | 25.0% | Long-tail portion of the model |
| 24 h | 6.25% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.39% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.02% | Low modeled remainder, not a clearance guarantee |
| 5.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Quetiapine within the antipsychotic group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
No nearby published profiles are available in this category.
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 6 h |
|---|---|
| Curve type | Normalized, first-order decline |
Selection note: Quetiapine labeling and clinical review support a parent-drug half-life near six hours. Norquetiapine, formulation, age, and CYP3A interactions add context that the parent curve cannot display.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: QUETIAPINE FUMARATE (QUETIAPINE) TABLET [COUPLER LLC].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Quetiapine.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the antipsychotic group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.